

Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022

<https://marketpublishers.com/r/G94E2C54C47EN.html>

Date: October 2017

Pages: 96

Price: US\$ 3,300.00 (Single User License)

ID: G94E2C54C47EN

Abstracts

This report studies the global Therapies for Resistant and Recurrent Metastatic Cancer market, analyzes and researches the Therapies for Resistant and Recurrent Metastatic Cancer development status and forecast in United States, EU, Japan, China, India and Southeast Asia.

This report focuses on the top players in global market, like

Miraca Holdings

Proteome Sciences

Boreal Genomics

Oxford Gene Technology

Illumina

Neogenomics Laboratories

Biotheranostics

Nanostring Technologies

Genomic Health

Thermo Fisher Scientific

Market segment by Regions/Countries, this report covers

United States

EU

Japan

China

India

Southeast Asia

Market segment by Type, Therapies for Resistant and Recurrent Metastatic Cancer can be split into

Breast Cancer

Endocrine Cancer

Leukemia

Lymphoma

Bladder

Colorectal

Kidney

Ovary

Pancreas

Others

Market segment by Application, Therapies for Resistant and Recurrent Metastatic Cancer can be split into

Chemotherapy

Hormone Therapy

Biotherapy

Radiation Therapy

Surgery

Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022

1 INDUSTRY OVERVIEW OF THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER

1.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Overview

1.1.1 Therapies for Resistant and Recurrent Metastatic Cancer Product Scope

1.1.2 Market Status and Outlook

1.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Analysis by Regions

1.2.1 United States

1.2.2 EU

1.2.3 Japan

1.2.4 China

1.2.5 India

1.2.6 Southeast Asia

1.3 Therapies for Resistant and Recurrent Metastatic Cancer Market by Type

1.3.1 Breast Cancer

1.3.2 Endocrine Cancer

1.3.3 Leukemia

1.3.4 Lymphoma

1.3.5 Bladder

1.3.6 Colorectal

1.3.7 Kidney

1.3.8 Ovary

1.3.9 Pancreas

1.3.10 Others

1.4 Therapies for Resistant and Recurrent Metastatic Cancer Market by End Users/Application

1.4.1 Chemotherapy

1.4.2 Hormone Therapy

1.4.3 Biotherapy

1.4.4 Radiation Therapy

1.4.5 Surgery

1.4.6 Others

2 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER COMPETITION ANALYSIS BY PLAYERS

2.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Players (2016 and 2017)

2.2 Competitive Status and Trend

2.2.1 Market Concentration Rate

2.2.2 Product/Service Differences

2.2.3 New Entrants

2.2.4 The Technology Trends in Future

3 COMPANY (TOP PLAYERS) PROFILES

3.1 Miraca Holdings

3.1.1 Company Profile

3.1.2 Main Business/Business Overview

3.1.3 Products, Services and Solutions

3.1.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)

3.1.5 Recent Developments

3.2 Proteome Sciences

3.2.1 Company Profile

3.2.2 Main Business/Business Overview

3.2.3 Products, Services and Solutions

3.2.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)

3.2.5 Recent Developments

3.3 Boreal Genomics

3.3.1 Company Profile

3.3.2 Main Business/Business Overview

3.3.3 Products, Services and Solutions

3.3.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)

3.3.5 Recent Developments

3.4 Oxford Gene Technology

3.4.1 Company Profile

3.4.2 Main Business/Business Overview

3.4.3 Products, Services and Solutions

3.4.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value)

(2012-2017)

3.4.5 Recent Developments

3.5 Illumina

3.5.1 Company Profile

3.5.2 Main Business/Business Overview

3.5.3 Products, Services and Solutions

3.5.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value)

(2012-2017)

3.5.5 Recent Developments

3.6 Neogenomics Laboratories

3.6.1 Company Profile

3.6.2 Main Business/Business Overview

3.6.3 Products, Services and Solutions

3.6.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value)

(2012-2017)

3.6.5 Recent Developments

3.7 Biotheranostics

3.7.1 Company Profile

3.7.2 Main Business/Business Overview

3.7.3 Products, Services and Solutions

3.7.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value)

(2012-2017)

3.7.5 Recent Developments

3.8 Nanostring Technologies

3.8.1 Company Profile

3.8.2 Main Business/Business Overview

3.8.3 Products, Services and Solutions

3.8.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value)

(2012-2017)

3.8.5 Recent Developments

3.9 Genomic Health

3.9.1 Company Profile

3.9.2 Main Business/Business Overview

3.9.3 Products, Services and Solutions

3.9.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value)

(2012-2017)

3.9.5 Recent Developments

3.10 Thermo Fisher Scientific

3.10.1 Company Profile

- 3.10.2 Main Business/Business Overview
- 3.10.3 Products, Services and Solutions
- 3.10.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
- 3.10.5 Recent Developments

4 GLOBAL THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET SIZE BY TYPE AND APPLICATION (2012-2017)

- 4.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Type (2012-2017)
- 4.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2012-2017)
- 4.3 Potential Application of Therapies for Resistant and Recurrent Metastatic Cancer in Future
- 4.4 Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer

5 UNITED STATES THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK

- 5.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
- 5.2 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

6 EU THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK

- 6.1 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
- 6.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

7 JAPAN THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK

- 7.1 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)

7.2 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

8 CHINA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK

8.1 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)

8.2 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

9 INDIA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK

9.1 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)

9.2 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

10 SOUTHEAST ASIA THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER DEVELOPMENT STATUS AND OUTLOOK

10.1 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)

10.2 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

11 MARKET FORECAST BY REGIONS, TYPE AND APPLICATION (2017-2022)

11.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Regions (2017-2022)

11.1.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)

11.1.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)

11.1.3 Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)

11.1.4 China Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)

11.1.5 India Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)

11.1.6 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)

11.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Type (2017-2022)

11.3 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2017-2022)

12 THERAPIES FOR RESISTANT AND RECURRENT METASTATIC CANCER MARKET DYNAMICS

12.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Opportunities

12.2 Therapies for Resistant and Recurrent Metastatic Cancer Challenge and Risk

12.2.1 Competition from Opponents

12.2.2 Downside Risks of Economy

12.3 Therapies for Resistant and Recurrent Metastatic Cancer Market Constraints and Threat

12.3.1 Threat from Substitute

12.3.2 Government Policy

12.3.3 Technology Risks

12.4 Therapies for Resistant and Recurrent Metastatic Cancer Market Driving Force

12.4.1 Growing Demand from Emerging Markets

12.4.2 Potential Application

13 MARKET EFFECT FACTORS ANALYSIS

13.1 Technology Progress/Risk

13.1.1 Substitutes

13.1.2 Technology Progress in Related Industry

13.2 Consumer Needs Trend/Customer Preference

13.3 External Environmental Change

13.3.1 Economic Fluctuations

13.3.2 Other Risk Factors

14 RESEARCH FINDING/CONCLUSION

15 APPENDIX

Methodology

Analyst Introduction

Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Therapies for Resistant and Recurrent Metastatic Cancer Product Scope

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) (2012-2017)

Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Regions in 2016

Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Type in 2016

Figure Breast Cancer Market Size (Million USD) and Growth Rate (2012-2017)

Figure Endocrine Cancer Market Size (Million USD) and Growth Rate (2012-2017)

Figure Leukemia Market Size (Million USD) and Growth Rate (2012-2017)

Figure Lymphoma Market Size (Million USD) and Growth Rate (2012-2017)

Figure Bladder Market Size (Million USD) and Growth Rate (2012-2017)

Figure Colorectal Market Size (Million USD) and Growth Rate (2012-2017)

Figure Kidney Market Size (Million USD) and Growth Rate (2012-2017)

Figure Ovary Market Size (Million USD) and Growth Rate (2012-2017)

Figure Pancreas Market Size (Million USD) and Growth Rate (2012-2017)

Figure Others Market Size (Million USD) and Growth Rate (2012-2017)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Share by Application in 2016

Table Key Downstream Customer in Chemotherapy

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million

USD) and Growth Rate in Chemotherapy (2012-2017)

Table Key Downstream Customer in Hormone Therapy

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Hormone Therapy (2012-2017)

Table Key Downstream Customer in Biotherapy

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Biotherapy (2012-2017)

Table Key Downstream Customer in Radiation Therapy

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Radiation Therapy (2012-2017)

Table Key Downstream Customer in Surgery

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Surgery (2012-2017)

Table Key Downstream Customer in Others

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate in Others (2012-2017)

Table Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2016 and 2017)

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017

Table Miraca Holdings Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Miraca Holdings (2012-2017)

Figure Miraca Holdings Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Proteome Sciences Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Proteome Sciences (2012-2017)

Figure Proteome Sciences Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Boreal Genomics Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Boreal Genomics (2012-2017)

Figure Boreal Genomics Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Oxford Gene Technology Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue

(Million USD) of Oxford Gene Technology (2012-2017)

Figure Oxford Gene Technology Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Illumina Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Illumina (2012-2017)

Figure Illumina Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Neogenomics Laboratories Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Neogenomics Laboratories (2012-2017)

Figure Neogenomics Laboratories Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Biotheranostics Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Biotheranostics (2012-2017)

Figure Biotheranostics Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Nanostring Technologies Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Nanostring Technologies (2012-2017)

Figure Nanostring Technologies Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Genomic Health Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Genomic Health (2012-2017)

Figure Genomic Health Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Thermo Fisher Scientific Basic Information List

Table Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue (Million USD) of Thermo Fisher Scientific (2012-2017)

Figure Thermo Fisher Scientific Therapies for Resistant and Recurrent Metastatic Cancer Business Revenue Market Share in 2016

Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Type (2012-2017)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2012

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2013

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2014

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2015

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2016

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2017

Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application (2012-2017)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2012

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2013

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2014

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2015

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2016

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2017

Table Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer

Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)

Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017

Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)

Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share

by Players in 2017

Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)

Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017

Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)

Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure China Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017

Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)

Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure India Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017

Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) and Growth Rate by Regions (2012-2017)

Table Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Players (2012-2017)

Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2016

Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Players in 2017

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Regions (2017-2022)

Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Regions (2017-2022)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Regions in 2017

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Regions in 2022

Figure United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)

Figure EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)

Figure Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)

Figure China Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)

Figure India Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)

Figure Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Million USD) and Growth Rate (2017-2022)

Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Type (2017-2022)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2017

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size Share by Type in 2022

Table Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application (2017-2022)

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2017

Figure Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Million USD) by Application in 2022

I would like to order

Product name: Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022

Product link: <https://marketpublishers.com/r/G94E2C54C47EN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G94E2C54C47EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

